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Abstract: Animal models have greatly enriched our understanding of the molecular 
mechanisms of numerous types of cancers. Gastric cancer is one of the most common 
cancers worldwide, with a poor prognosis and high incidence of drug-resistance. However, 
most inbred strains of mice have proven resistant to gastric carcinogenesis. To establish 
useful models which mimic human gastric cancer phenotypes, investigators have utilized 
animals infected with Helicobacter species and treated with carcinogens. In addition, by 
exploiting genetic engineering, a variety of transgenic and knockout mouse models of 
gastric cancer have emerged, such as INS-GAS mice and TFF1 knockout mice. 
Investigators have used the combination of carcinogens and gene alteration to accelerate 
gastric cancer development, but rarely do mouse models show an aggressive and metastatic 
gastric cancer phenotype that could be relevant to preclinical studies, which may require 
more specific targeting of gastric progenitor cells. Here, we review current gastric 
carcinogenesis mouse models and provide our future perspectives on this field. 
Keywords: gastric cancer; mouse model; metaplasia; Helicobacter felis; Helicobacter 
pylori; INS-GAS mice 
 
1. Introduction 
Gastric cancer remains the 2nd leading cause of cancer mortality worldwide, with an overall 5-year 
survival rate that is less than 25% [1,2]. Critical to understanding the mechanisms involved in gastric 
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cancer, and devising preventive and therapeutic interventions, is the need to develop an authentic 
animal model. Mice have a different gastric anatomy compared to humans. In mice the gastric fundus 
equivalent is lined by squamous, rather than oxyntic glandular epithelium. Thus, in mice, the 
squamocolumnar junction does not universally approximate the gastroesophageal junction as it does in 
normal human anatomy. In addition, rodents rarely develop spontaneous gastric cancer, although some 
reports have described spontaneous gastric adenocarcinomas in cotton rats (Sigmodon hispidus), and in 
the Z strain of the African rodent Mastomys natalensis [3–7]. However, these animals when they 
develop gastric tumors more frequently exhibit enterochromaffin-like cell carcinoids. Thus, 
experimental efforts have focused on identifying chemical, infectious or genetic means to induce 
gastric cancer in animals. 
Prior to the discovery of Helicobacter pylori infection, major etiological factors were thought to be 
a diet rich in salt and nitrates/nitrites, along with a low intake of ascorbic acid and carotenoids [8], and 
thus early animal models utilized nitrosamines, such MNNG in rats [9,10] and MNU in mice to induce 
gastric tumors [11]. 
With the discovery of H. pylori by Marshall and Warren [12], and subsequently studies showing a 
strong association with gastric cancer [13–17], the focus shifted to the development of animal models 
of Helicobacter-associated gastric cancer. A variety of animals, including mice, rats, Mongolian 
gerbils, cats, guinea, pigs, ferrets, pigs, and macaques, have been experimentally infected with a 
variety of different Helicobacter species. Because of the ability to manipulate the mouse genome, mice 
have become the animal model of choice for cancer research. While the greatest interest has been in 
mouse models, only a limited number of H. pylori strains have been identified that successfully 
colonize the mouse stomach. The most robust and useful models to date have been H. pylori  
SS1-infected mice, and H. felis originally isolated from the stomach of cats and dogs [18]. Both of 
these gastric Helicobacters are capable of long-term colonization and have the ability to induce 
chronic gastritis and precancerous lesions in mice. However, the SS1 strain is not able to induce gastric 
cancer in most inbred strains of mice, while it does cause gastric carcinoma in C57BL/129  
mice [19,20]. Chronic H. felis infection has been shown to induce severe inflammation, atrophy, 
metaplasia, dysplasia and gastric cancer in C57BL/6 mice [21]. 
While genetically engineered mouse models of cancer were developed in the 1980’s, transgenic 
models of gastric cancer were slow to emerge. Initial models included some containing a variety of 
oncogenes that were known to transform but had no known association with human gastric cancer, 
such as the SV40 T antigen, which binds to pRb and disrupts its function [22]. Human carcino-embryonic 
antigen (CEA) promoter/SV40 T antigen transgenic mice were reported to develop antral hyperplasia 
or gastric cancer [23,24]. Stomach-specific SV40 T antigen transgenic mice using H/K-ATPase-β 
subunit gene promoter [25] developed hyperplasia and abnormal cell distribution within the gastric 
glandular unit, and rarely developed dysplasia. Other early models included transgenic mice carrying 
the human adenovirus type 12 (Ad12) early region 1 under control of the mouse mammary tumor  
virus (MMTV) long terminal repeat (LTR), which developed adenocarcinoma or adenosquamous 
carcinoma [26]. In addition, transgenic mice expressing HPV-16 early region of the bovine keratin 6 
gene promoter developed glandular stomach tumors [27]. However, these models did not progress to 
cancer through the atrophy-metaplasia-dysplasia sequence, as described by Correa [28], nor were they 
associated with Helicobacter infection or chronic inflammation. 
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INS-GAS mice as a model of spontaneous gastric cancer were first described in 2000. These mice 
were reported to develop atrophic gastritis and intestinal metaplasia, followed by corpus cancer with a 
high incidence rate, and tumor development was accelerated by H. felis infection, suggesting that this 
model closely mimicked the clinical course of human gastric carcinogenesis [29]. This initial mouse 
model was followed by the H/K-ATPase-IL-1β transgenic mice, which progressed through the 
atrophy-metaplasia-dysplasia sequence and validated human genetic data that implicated the IL-1β 
gene locus as a major risk factor for gastric cancer [30]. Other studies using genetic mouse models of 
gastric cancer have been reported, and are detailed below. These genetic mouse models have provided 
considerable insight on the role of the stroma, also known as the tumor microenvironment, which has 
been recognized as a critical factor in various types of cancer. Modulation of cytokines, chemokines or 
the signaling pathways upstream has also demonstrated unequivocally the importance of inflammatory 
responses in gastric cancer development [31–34]. 
Nevertheless, despite the significant advances made utilizing diverse mouse models, these models 
have all shown some limitations, including modest gastric pathology, slow time course, and the 
absence of invasive or metastatic tumors. In addition, it is important to keep in mind that the response 
to infection or genetic manipulation is highly dependent on the mouse genetic background, gender, diet 
and housing conditions. Animal stress associated with overcrowding, inadequate sanitation, and 
variations in temperature, humidity, and light cycles may predispose resistant animals to adverse 
disease outcomes. Especially in the case of the enterohepatic Helicobacter species, differences in study 
outcomes may be attributed to persistent colonization by these murine Helicobacters [35–37]. 
Here we review these genetic or chemical models of gastric carcinogenesis, and compare their 
pathological features, limitations and contribution to our understanding of gastric carcinogenesis.  
We also emphasize the impact of comprehensive genomic analysis on new or emerging transgenic 
mouse models. 
2. Chemical Carcinogenesis Models of Gastric Cancer 
To explore the mechanisms of gastric cancer development and establish a useful animal model of 
gastric tumorigenesis, investigators examined the utility of a variety of chemical carcinogens. In 
particular, researchers focused on N-nitroso compounds, which are generated in the stomach by 
anaerobic bacteria following ingestion of nitrates and nitrites, which were thought to be an important 
inducer of human cancer. N-methyl-N-nitro-N-nitrosoguanidine (MNNG) was the first nitrosamine 
shown by researchers to induce stomach tumors in rats. In 1966, Schoental et al. administered MNNG 
to rats using a stomach tube, resulting in squamous cell carcinoma in the rat forestomach [38]. In 1967, 
Sugimura et al. modified their method, administering MNNG orally to rats continuously in the drinking 
water, and achieved for the first time a high incidence of antropyloric adenocarcinoma [10]. MNNG 
was later found to be a very potent gastric carcinogen in Mongolian gerbils [39,40]. Exposure to 400 ppm 
MNNG in drinking water for 50 weeks resulted in gastric adenocarcinomas in 63.6% of gerbils [40]. Using 
MNNG-induced gastric cancer model, it has been reported that administration of high-salt diet [41,42], 
calcium-deficient diet [43], catechol [44], or IL-1β [45] promotes gastric cancer development. 
Rats and gerbils are limited as model systems, given the absence of genetic models, and thus 
investigators explored the effect of oral administration of nitrosamines in inbred strains of mice. 
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However, mice proved to be remarkably resistant to MNNG-induced gastric carcinogenesis. Danon et al. 
infected female Balb/c mice with H. heilmannii and administered 150 ppm MNNG in drinking water 
for 38 weeks and found that the treated mice developed squamous cell carcinomas in the mouth and 
forestomach, but not adenocarcinoma in the glandular stomach [46]. 
Researchers then explored the utility of N-methyl-N-nitrosourea (MNU) as a gastric carcinogen in 
mouse models. Tatematsu et al. treated Balb/c mice with 0.5 mg MNU by weekly intragastric 
intubation, but found that most of the mice died due to squamous cell carcinoma in the forestomach. 
Interestingly, when the mouse forestomach was removed surgically prior to MNU treatment,  
well-differentiated adenocarcinoma developed in the glandular stomach with 100% incidence rate by 
40 weeks [11]. Thus, the glandular stomach was indeed sensitive to the carcinogenic effects of MNU, 
but the phenotype was obscured by the greater sensitivity of the forestomach, at least at that specific 
dose and route of administration. Tatematsu et al. went on to demonstrate that 30–120 ppm MNU 
given in drinking water was preferable to oral gavage, without the induction of tumors of the 
forestomach [47]. The efficiency of tumor induction by MNU was found to depend on its 
concentration rather than total intake [48], and MNU in the drinking water at 240 ppm on alternate 
weeks (total exposure; 5 weeks) was effective in inducing gastric cancer in 6 strains of mice that were 
studied [49]. Consequently, the protocol of 240 ppm MNU treatment in the drinking water for 5 weeks 
(every other week) is currently a standard and widely used murine method of gastric carcinogenesis. 
MNU-induced tumors in mice are located mainly in the gastric antrum, and pathologically are 
uniformly well- or moderately-differentiated adenocarcinomas (Figure 1). The tumors are rich in 
stromal cells, and occasionally invade into the submucosa although signet ring-cell carcinoma and 
metastatic tumors are rarely, if ever seen. 
The MNU mouse model of gastric cancer has been extensively used for investigating the role of 
various signaling pathways or transcription factors in gastric carcinogenesis, including the roles of  
p53 [50], NF-κB [51], MAPK pathway [52,53], Cox-2 [54,55], β-catenin [54], E-cadherin [56], and 
KLF4 [57]. Although MNU is an alkylating agent that can potentially induce the formation of DNA 
adducts and GC > TA transversion mutations, only rare mutations have been observed in N-nitroso-
compounds (NOC)-induced gastric tumors of rodents [58], raising questions about the precise 
mechanism of carcinogenesis. MNU is also known to modify amino acids in histone proteins, 
especially histone H3 lysine residues, leading to chromatin remodeling [59]. Indeed, MNU treatment 
in mice affects the expression of TFF1, an important gastric-specific tumor suppressor gene, through 
epigenetic modifications. DNA and histone methylation, and promoter methylation of the TFF1 gene 
have also been observed in human gastric cancer [60]. This suggests that epigenetic effects are likely 
to constitute a key mechanism of NOC-induced carcinogenesis. 
One potential criticism of the MNU mouse model of gastric cancer is the absence of Helicobacter 
spp.-associated chronic inflammation. While the MNU model does not proceed through a classical 
atrophy-metaplasia-dysplasia sequence, this latter H. pylori-dependent pathway results in achlorhydria 
with subsequent bacterial overgrowth; NOCs may be generated from nitrates and nitrites in this setting, 
and thus the argument can be made that the generation of N-nitroso compounds may play a role in 
Helicobacter-associated carcinogenesis. A recent study used a combination of MNU and H. felis 
infection [60], and achieved a very rapid induction of antral gastric cancer. This same combination was 
reported to induce a high frequency of gastric cancer in H. pylori-infected Mongolian gerbils compared 
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to gerbils receiving MNU only [61,62]. Thus, the combination of Helicobacter spp. infection followed 
by MNU treatment mimics in some ways the proposed pathogenesis of human antral carcinogenesis. 
Figure 1. MNU-induced mouse tumor. Top panels: Low and high magnification images of 
the distal corpus showing gastric dysplasia (glandular proliferation with architectural 
distortion and cytological atypia in the superficial half of the mucosa) associated with 
oxyntic loss and pyloric-type glandular metaplasia. (Bar: Left 200× or 80 μM, Right 400× 
or 40 μM) Bottom panels: Low and high magnification images of a gastric tumor biopsy 
specimen showing dysplastic glands with lamina propria invasion, effacement and 
associated desmoplasia and inflammation. (Bar: Left 100× or 160 μM, Right 400× or 40 μM). 
 
3. Helicobacter Infection Models 
Given the key role of Helicobacter pylori infection in the etiology and pathogenesis of gastric 
cancer, researchers pursued the development of animal models of gastric Helicobacter infection. The 
first studies supporting a potent carcinogenic role for Helicobacter species in the gastric mucosa was 
the ferret model of Helicobacter mustelae infection [63–65]. Ferrets naturally infected with  
H. mustelae exposed to one dose of 100 mg/kg MNNG developed gastric cancer, while H. mustalae 
infected ferrets did not [63]. Unfortunately, SPF ferrets not infected with H. mustelae were not 
available to ascertain whether these animals also would develop MNNG-induced gastric cancer. 
Subsequently, aged H. mustelae-infected ferrets have been reported to develop gastritis, dysplasia, and 
gastric adenocarcinoma [66]. 
With respect to H. pylori, several H. pylori strains, such as the G1.1 strain [67], the TN2 strain [68], 
or the B128 strain [69], have the ability to colonize Mongolian gerbils, and induce gastric 
adenocarcinoma. This has allowed researchers to infect Mongolian gerbils with a variety strains, 
including their isogenic mutants, in order to investigate the importance of bacterial virulence factors in 
gastric carcinogenesis [67,68,70]. 
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Interestingly, mice in general and the C57BL/6 strain in particular are proved to be remarkably 
resistant to colonization with various H. pylori strains [71,72]. Thus, alternative mouse models of 
gastric Helicobacter infection were explored. In 1990, Helicobacter felis, a close relative of H. pylori 
that was isolated from the cat stomach, was shown to readily colonize the mouse stomach in large 
numbers [73]. Several papers reported that H. felis had the ability to induce severe gastritis and atrophy 
in mice [73–75]. Moreover, with a longer time period of observation, analysis of H. felis-infected mice 
showed gastric metaplasia, dysplasia and invasive cancer [21,76]. After 12–16 months of infection, 
extensive dysplastic lesions were evident in the gastric corpus at the squamocolumnar junction (SCJ) 
along the lesser curvature. After more extended periods of infection (up to 2 years), large polypoid 
antral tumors develop and mimic closely lesions found in humans infected with H. pylori [77,78]. In 
the H. felis infection model, eradication of Helicobacter infection at early time points led to a 
regression of inflammation, restoration of parietal cells, reestablishment of normal architecture, and 
prevention against development of adenocarcinoma. Bacterial eradication at 1 year was also associated 
with the reappearance of parietal cells and partial restoration of architecture. Thus, eradication studies 
in mice have revealed that inflammation, metaplasia, and dysplasia are reversible with early 
eradication therapy, and that progression to dysplasia can be arrested with eradication therapy at a later 
time point [79,80]. In humans, eradication of H. pylori in patients with gastritis but not dysplasia is 
linked to a decrease in the incidence of gastric adenocarcinoma epidemiologically [81,82], thus 
supporting findings in mouse models. Antibiotic treatment to eradicate H. pylori in gerbils and  
INS-GAS mice also arrests progression to gastric lesions [73,83]. 
Strains of H. pylori that can colonize mice—the so-called ―mouse adopted strains of H. pylori‖—have 
been developed. Among H. pylori mouse adapted strains reported to date, the Sydney strain of  
H. pylori (SS1) has been the best characterized and most useful in murine model systems [20]. 
Relatively high levels of colonization were achieved in inbred C57BL/6 mice, while colonization 
levels in Balb/c, DBA/2, and C3H/He strains were lower [20]. After 8 months of infection, active 
gastritis and severe atrophy were observed, along with detectable levels of bacteria [20]. However, 
even with a 2-year follow-up, lesions did not progress to gastric cancer in mice infected with SS1 or 
other strains, 119p and G50, although some mice developed gastric lymphoma [84]. H. pylori SS1 
infection did result in development of carcinomas in situ in C57BL/129 mice 15 months after  
infection [19]. H. pylori infection also causes gastric cancer in genetically modified mice, for example, 
INS-GAS mice (see below) [85]. 
In H. pylori, the cag pathogenicity island (cag-PAI), a 40-kb genomic fragment containing 31 genes, 
encodes a type IV secretion (TFSS) apparatus used to inject bacterial proteins such as the 120-kilodalton 
protein CagA into host epithelial cells [78]. A series of in vitro reports have established that injection 
of CagA into host cells leads to phosphorylation of CagA by host cell kinases, resulting in activation of 
SHP-2 tyrosine phosphatase, NF-κB signaling pathways, and MAPK signaling pathways [86–88]. The 
H. pylori peptidoglycan is also injected into host cells via the type IV secretory system, leading to 
activation of Nod1, an intracellular pathogen recognition molecule with specificity for gram-negative 
peptidoglycans [89], and mice deficient in Nod1 are more susceptible than wild-type (WT) mice to 
infection by cag-positive strains of H. pylori [89]. 
Interestingly, while the H. pylori SS1 strain was initially reported to possess an intact cag-PAI, the 
SS1 strain used in subsequent studies does not appear to express CagA, which may be explain to some 
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extent the limited virulence of SS1 in mice [90]. Systemic expression of CagA in transgenic mice has 
led to the development of gastrointestinal and hematological malignancies [91]. mice deficient in Nod1 
are more susceptible than wild-type mice to infection by cag-positive strains of H. pylori [89]. Arnold 
et al. used CagA-positive SS-1 (PMSS1, which was original strain isolated from a patient) and showed 
that mice infected with PMSS1 rapidly develop gastritis, gastric atrophy, epithelial hyperplasia, and 
metaplasia in a type IV secretion system-dependent manner [92]. These results suggest that CagA 
and/or the cag-PAI may play an important role in gastric carcinogenesis. Nevertheless, in mice,  
cag-negative strains such as H. felis appear to be at least as carcinogenic as cag-positive H. pylori 
strains. Although the ability of PMSS1 to inject CagA into host cells decreases gradually after 1 month 
infection and disappear after 3 months, strong inflammation and phenotypic changes could be 
sustained for more than 6 months [92]. In addition, inactivation in a H. pylori strain of the cagE gene 
coding for TFSS delayed the progression to carcinoma, but neoplasia ultimately developed in all 
infected INS-GAS mice with the H. pylori mutant [85]. Thus, taken together, these observations might 
suggest that the induction of gastric preneoplasia in mice is affected by host factors, such as the 
inflammatory response or other genetic factors. 
Support for the importance of host genetic factors modulating gastric carcinogenesis includes 
observations regarding Helicobacter colonization of various inbred mouse strains, which revealed 
markedly different responses [75,76,93]. For example, the C57BL/6 strain is more sensitive than the 
Balb/c strain to H. felis-induced gastric atrophy. Potential explanations include the more T-helper-1 
(Th1)-dependent immune response in C57BL/6 mice, compared to a Th2-dominant immune response 
in Balb/c mice [76], or possibly the reduced activity of phospholipase A2 in C57BL/6 mice [76,94]. 
Susceptible strains such as C57BL/6 mice show much higher levels of pro-inflammatory cytokines 
such as IFN-γ. The use of immunodeficient mice or mice which are deficient or overexpressing 
cytokines such as IFN-γ, IL-10, IL-4, or IL-7, have been useful for investigating the role of the host’s 
immune system in development and severity of gastritis and following mucosal changes [32,95–102]. 
In addition, in susceptible strains such as C57BL/6 mice, H. felis-induced proliferation and apoptosis 
are markedly increased compared with resistant strains [76]. The role of apoptosis was further studied 
through the combination of Helicobacter infection and mice which lack apoptosis-related genes, such 
as Fas [103,104], p53 [21], or IKK-β [105]. These studies have supported the notion that increased 
apoptosis is critical in the development of atrophy, metaplasia, and dysplasia. 
Mouse models of Helicobacter infection have been used to examine the role of other co-factors in 
gastric carcinogenesis, such as gender, diet, and co-infection. Gender may be important, since gastric 
cancer is much more prevalent in men compared to women. Helicobacter infection of some murine 
strains, such as H. felis or H. pylori infection of INS-GAS mice (see below), results in greater gastric 
carcinogenesis in male mice compared to female mice [85,106]. However, C57BL/6 mice infected 
with H. felis did not show significant gender differences in the incidence of gastric carcinoma [21,85], 
suggesting the different mechanisms of carcinogenesis in these models. Indeed, some studies of 
Helicobacter infection in mice indicate that female C57BL/6 mice are more susceptible to gastric 
disease [107,108]. High salt diets, and diets rich in nitrates and nitrites, have been associated with an 
increased gastric cancer risk. Treatment with N-nitroso compounds, such as MNU, prior to H. pylori 
infection caused more severe preneoplastic changes and increased gastric cancer as mentioned  
above [109,110]. C57BL/6 mice infected with SS1 and fed a high-salt diet developed more pronounced 
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gastric atrophy and foveolar hyperplasia [111]. Concurrent parasitic infection may also alter the effects 
of Helicobacter infection. Co-infection of C57BL/6 mice with the helminth, Heligmosomoides 
polygyrus, along with H. felis, reduced the severity of gastric atrophy and preneoplastic lesions seen 
with H. felis alone [112]. This was associated with a shift from the usual Th1 mucosal immune 
response to a polarized Th2 response. Finally, gastric atrophy due to chronic H. pylori infection is 
associated with bacterial overgrowth, which has been postulated to be an additional risk factor for 
gastric cancer. Germ-free INS-GAS mice infected with H. pylori developed less severe and delayed 
gastric preneoplastic lesions compared with SPF-conditioned INS-GAS mice [113], suggesting that 
commensal bacterial flora in the stomach also influenced the development of gastric cancer. 
Mouse models of Helicobacter-induced gastric cancer make it possible to explore the origin of 
cancer cells and surrounding tissues. By using a bone marrow transplantation technique, Houghton et al. 
reported that chronic infection of C57BL/6 mice with H. felis results in population of the stomach with 
bone marrow-derived cells (BMDCs), and that these cells progress through metaplasia and dysplasia to 
intraepithelial cancer [114]. These findings were confirmed in an independent study, which showed that 
H. pylori infection also recruits and accumulates BMDCs in gastric epithelium [115]. Fibroblasts around 
gastric cancer, which have been called cancer-associated fibroblasts (CAFs) recently, are expanded by 
H. felis infection, and they were reported to be partly derived from bone marrow [31,116]. 
Taken together, studies to date have demonstrated that mouse models of chronic Helicobacter 
infection are robust and reproducible models that provide insights into the molecular mechanism of 
gastric carcinogenesis. However, there are limitations to Helicobacter mouse models, which include: 
the limited strains of H. pylori, particularly cag positive strains, that are able to colonize in mice; the 
slow time course for the development of tumors; the low incidence rate of advanced or invasive gastric 
cancer; anatomical differences (e.g., forestomach) between human and mice; the predominance of high 
grade dysplasia/early gastric cancers; and the absence of metastatic disease in these carcinogenesis models. 
4. Genetically Engineered Mouse Models 
Progress in genetic engineering technology leading to the development of transgenic or knockout 
mice has been useful for developing additional models of gastric cancer that have also shed light on 
the role of host genetic factors in gastric cancer development. These have included overexpression (or 
deficiencies) of growth factors and cytokines, as well as mutation of classical tumor suppressor genes 
and oncogenes. Below we have summarized six sets of animal models that have been reasonably well 
validated and that have provided unique insights into the pathogenesis of gastric adenocarcinoma. In 
addition, we mention briefly several other useful genetic models. 
4.1. INS-GAS Mice 
Although Zollinger-Ellison syndrome patients associated with syndrome type I MEN are likely to 
develop ECL cell carcinoid tumors [117], clear evidence of epidemiological correlation between 
hypergastrinemia and gastric cancer in human has not been reported. However, a subset of patients 
infected with H. pylori show mild-moderate increases in circulating levels of amidated gastrin, and 
thus a role for gastrin in gastric cancer was suggested, given its known role as a growth factor for the  
stomach [118]. Twenty years ago, the insulin-gastrin (INS-GAS) transgenic mice were created, 
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initially to study the role of gastrin on pancreatic islet cell formation [119]. The INS-GAS transgene 
consisted of the insulin promoter upstream of the human gastrin coding sequences, and resulted in the 
overexpression of amidated gastrin (primarily G-17) in the pancreatic β-cells, leading to two-fold 
elevations in serum levels of human amidated gastrin. When crossed with MT-TGF-α transgenic mice, 
the combination of gastrin and TGF-α was able to synergistically stimulate islet growth, although 
neither peptide alone was sufficient to stimulate pancreatic islet growth [120]. However, given the 
increases in circulating gastrin, subsequent investigations focused on the effects of gastrin on the 
gastric mucosa [29]. Young INS-GAS mice showed increased maximal gastric acid secretion and 
parietal cell mass, but interestingly progressed later to decreased parietal cell mass (atrophy), 
hypochloryhydria and worsening hypergastrinemia, in association with increased epithelial 
proliferation [29,121,122]. Over time, INS-GAS mice (in an FVB background) showed progression to 
gastric metaplasia and dysplasia, with the development of invasive gastric cancer in the corpus at  
20 months of age (Figure 2). Infection of INS-GAS mice with H. felis or H. pylori led to accelerated 
development of intramucosal carcinoma (in <12 months), with submucosal invasion and intravascular 
invasion [29,85]. Interestingly, the FVB/N inbred strain was most susceptible, while uninfected INS-GAS 
mice in a C57BL/6-background also developed mild gastric corpus hyperplasia and low-grade 
dysplasia [123], they did not progress to gastric cancer, even in the setting of H. felis infection. 
Figure 2. INS-GAS mouse tumor. Gross image: Stomach of a H. pylori-infected male  
INS-GAS mouse at 7 mpi showing coalescing diffuse tumors of the glandular stomach. 
Bottom panels: Low and high magnification H&E images of the stomach of an Hp-infected 
male INS-GAS mouse at 7 mpi showing diffuse high grade dysplastic/neoplastic glandular 
proliferation with lamina propria invasion consistent with the diagnosis of intramucosal 
carcinoma. Other features present include prominent mixed inflammation, erosions, 
mucosal/glandular degeneration/necrosis, glandular ectasia, oxyntic loss, severe hyperplasia, 
pseudopyloric and foveolar type metaplasia as well as glandular herniation. 
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Although H. pylori infection on its own is slow to induce gastric atrophy, and is unable to induce 
gastric cancer in the majority of strains of WT mice, it is highly effective as a gastric carcinogen in 
INS-GAS mice. Thus, multiple studies from independent laboratories have now confirmed that  
H. pylori infection of INS-GAS mice leads to accelerated gastric cancer. The model has been widely 
used, particularly to examine the importance of various kinds of gene expressions [34,124–128], 
antagonists or inhibitors [129,130], bacterial factors or commensal flora [80,83,85,113], gender 
difference or sex hormones [106,131–133], dietary cofactors [134], and apoptotic factors [135,136] in 
gastric carcinogenesis, as well as to analyze non-gastric diseases such as colon cancer [137,138], 
intestinal crypt regeneration [139], or iron-deficiency anemia [140] (Table 1). In addition, the model 
has proved highly useful for studies of cancer prevention, given the high degree of reproducibility and 
the relative rapid development of cancer in this model. 
Table 1. Applications of INS-GAS mouse model. 
Purpose of analysis Results 
Pancreatic islet cell formation [120] gastrin and TGF-α synergistically stimulate islet growth 
H. pylori and gastric mucosa [29] progression to gastric atrophy, metaplasia, dysplasia, and cancer 
Colonic carcinogenesis by AOM [137,138] progastrin, not gastrin, promotes colon carcinogenesis 
Gender differences [85,106] greater gastric carcinogenesis in male INS-GAS mice with H. pylori 
Importance of CagE [85] 
loss of cagE temporally retards but does not abrogate cancer 
progression 
Interaction with G-Gly [124] 
G-gly synergizes with amidated gastrin to stimulate acid secretion 
and inhibits atrophy 
CCK2R and Histamine receptor inhibitors 
[129] 
CCK2R and H2R antagonists synergistically inhibit gastric atrophy 
and cancer 
Intestinal crypt regeneration [139] hypergastrinemia increases regeneration of intestinal injury 
Apoptosis of gastric epithelium [135,136] gastrin induces apoptosis and contribute to gastric carcinogenesis 
Gene expression profiling [125] identify up- and down-regulating genes among 12,000 cDNA 
TFF2 expression [126] 
TFF2 expression in the gastric fundus was elevated in  
INS-GAS mice 
Swedish variant of moist oral smokeless 
tobacco [134] 
tobacco promotes cancer formation in H. pylori-infected  
INS-GAS mice 
Reg-1 expression [127] 
Reg1 is increased in the stomachs of H. felis-infected  
INS-GAS mice 
Role of 17-beta-estradiol [131–133] 
17beta-estradiol has protective effects on gastric cancer 
development 
Eradication of Helicobacter [79,80,83] eradication inhibits mouse gastric carcinogenesis 
Commensal bacterial flora in the  
stomach [113] 
SPF mice are more susceptible to gastric cancer than germ-free 
mice 
Antral carcinogenesis [60,123] gastrin suppresses antral carcinogenesis 
HB-EGF, MMP-7, EMT protein [128] 
neutralisation of gastrin in INS-GAS mice reduced MMP-7,  
HB-EGF and EMT proteins 
Acetic acid and cytoreduction [130] 
acetic acid could be a potent cytoreductive treatment of  
gastric cancer 
Effect of IL-8 [34] IL-8 promotes gastric carcinogenesis in INS-GAS mice 
H. pylori-induced iron deficiency [140] 
marked changes in expression of gastric iron transporters in  
H. felis-infected INS-GAS mice 
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4.2. Gastrin Knockout Mice 
As noted above, while a subset of H. pylori-infected patients exhibit significant hypergastrinemia 
(e.g., 2-fold elevations in gastrin), most patients infected with H. pylori do not. In fact, many H. pylori 
infected patients with pan-gastritis who develop gastric atrophy show depressed levels of circulating 
gastrin. Thus, it was not entirely surprising when several laboratories reported that gastrin knockout 
(GAS-KO or GAS
−/−
) mice were also susceptible to stomach cancer. However, in contrast to the 
hypergastrinemic INS-GAS mice which developed corpus cancers, GAS
−/−
 mice exhibited antral 
gastric cancers. GAS
−/−
 mice (C57BL/6 strain) were first generated by Koh et al., and the initial 
phenotype reported was fairly unremarkable, with mild changes in gastric architecture, including a 
slight decrease in the number of parietal and enterochromaffin-like cells [141]. However, an 
independent group reported that a separate line of 129/Sv GAS
−/−
 mice, showed hypochlorhydria and 
bacterial overgrowth, resulting in increased gastric inflammation [142]. Moreover, these GAS
−/−
 mice 
that were kept in conventional (non-SPF) housing conditions developed spontaneous antral tumors [143]. 
These findings were confirmed by an independent group, and the GAS
−/−
 mice were also found to be 
more susceptible to MNU-induced antral cancer compared to WT mice in the same genetic 
background [60]. 
Taken together, these reports suggest that gastrin has distinct functions in the gastric corpus and 
gastric antrum. Indeed, in contrast to the gastrin response observed in the corpus, hypergastrinemic 
INS-GAS FVB mice infected with H. felis showed decreased mucosal changes in the antrum relative 
to WT mice [123], and INS-GAS mice were found to be more resistant to MNU-induced antral  
tumors [60]. The antral tumor suppressive function of gastrin could be explained to some extent by its 
effect on stimulating acid secretion leading to inhibition of bacterial overgrowth. However, Dimaline 
et al. first reported that gastrin regulates TFF1 gene expression, providing a link between gastrin and a 
known tumor suppressor gene (see below). Tomita et al. went on to demonstrate that gastrin regulates 
TFF1 expression in vivo and in vitro through DNA methylation and histone modification [60]. 
Therefore, these studies suggest that amidated gastrin (e.g., G-17) increases corpus proliferation and 
cancer susceptibility, but (through TFF1) decreases antral proliferation and cancer susceptibility. The 
distinct effects of gastrin on proximal versus distal gastric cancers are consistent with the distinct 
epidemiology and behavior of tumors at these two anatomical sites, and emphasizes the importance of 
pathological descriptions clearly distinguishing the corpus and the antrum as separate tumor sites. 
4.3. TFF1 Knockout Mice and Gp130 Mutant Mice 
The human and mouse TFF1 (formerly known as pS2) proteins belong to the family of trefoil 
peptides, which are characterized by the presence of one to six cysteine-rich P domains. TFF1 proteins 
are normally expressed in the epithelial cells of the gastric mucosa, and are abnormally expressed in 
gastrointestinal diseases and various cancers. To elucidate the function of TFF1, Lefebvre et al. 
disrupted the mouse TFF1 gene by homologous recombination, generating TFF1
−/−
 mice (F2 129/Svj 
mixed background) [144]. Mice deficient in TFF1 expression displayed hyperplastic gastric epithelium 
with markedly elongated gastric pits, and multifocal intraepithelial or intramucosal carcinomas were 
observed in 30% of mice [144]. A recent study has shown that loss of TFF1 leads to activation of IKK 
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complex-regulated NF-κB transcription factors, resulting in enhanced NF-κB-mediated inflammatory 
responses during the progression to gastric tumorigenesis [145]. 
A reduction in TFF1 gene expression has been observed in about 50% of human distal stomach 
cancers, and promoter hypermethylation has also been found rather than mutation of the TFF1  
gene [146–148]. A well-defined positive transcriptional regulator of TFF1 is the peptide hormone 
gastrin [149]. Gastrin inhibits TFF1 repression and thus suppresses MNU-induced antral gastric 
carcinogenesis [60]. In Helicobacter-infected human or mouse tissues, TFF1 was moderately 
epigenetically repressed, but much greater TFF2 repression was observed in stomach cancer [60]. 
Clyne et al. reported that H. pylori bound to the TFF1 dimer in vitro and that this interaction enables 
binding to gastric mucin, suggesting that TFF1 may act as a receptor for the organism [150,151]. 
However, in vivo evidence for direct H. pylori-TFF1 interaction has been lacking. Thus, further studies 
are needed to clarify the possible association between TFF1 and H. pylori. 
While TFF1 is expressed predominantly in foveolar surface mucous or pit cells of the stomach, 
TFF2 is expressed in the deeper glandular epithelium in the distal stomach and the acini of Brunners 
glands in the duodenum [152–154]. Genetically engineered mice deficient in TFF2 show a minimal 
phenotype, with only a slight reduction in proliferation rates in the gastric mucosa [155] but H. pylori-
infected TFF2-deficient mice develop more advanced premalignant lesions of atrophy, metaplasia, and 




 mice displayed glandular 
atrophy and metaplasia. These results suggest that TFF2 negatively regulates preneoplastic progression 
and subsequent tumor development in the stomach [157]. 
Gp130 is a common co-receptor for the cytokines IL-6 and IL-11. Mice with a mutation of the 
gp130 receptor (gp130
F/F
 mice), which abrogates Src-homology tyrosine phosphatase 2 (SHP2)-Ras-
ERK signaling following gp130 engagement, have a dramatic gastric phenotype. Gp130
F/F
 mice 
progress rapidly to gastric neoplasia, with evidence of gastric adenomas by 3 months of age [158,159]. 
Interestingly, mutation of the gp130 receptor leads to downregulation of the TFF1 gene, and the 
phenotype of gp130
F/F
 mice in many ways mimics that of TFF1
−/−
 mice. The main cytokine driver of 
gp130 signaling in the stomach is IL-11, with IL-6 having little activity in the antral stomach [160,161]. 
IL-11 appears to promote chronic gastric inflammation and associated tumorigenesis mediated by 
excessive activation of STAT3 and STAT1 [162]. 
4.4. H/K-ATPase-IL-1β Transgenic Mice 
Polymorphisms of the IL-1β that are predicted to increase IL-1β signaling have been shown to 
increase the risk of a number of human tumors, particularly gastric cancer [30]. IL-1β is a pleiotropic 
proinflammatory cytokine that has profound effects on inflammation and immunity, and is upregulated 
by H. pylori infection [30]. Tu et al. generated stomach-specific expression of human IL-1β in 
transgenic mice by using the murine H/K-ATPase promoter to direct expression of a constitutively 
active form of human IL-1β. H/K-ATPase-IL-1β transgenic mice (C57BL/6 background) exhibited 
spontaneous gastric inflammation and slow progression (over 1.5 years) to gastric atrophy, metaplasia 
and gastric cancer (Figure 3). In addition, infection of these mice with H. felis resulted in strong 
synergy and rapid progression (in <1 year) to cancer [163]. Thus, H/K-ATPase-IL-1β transgenic mice 
confirm the genetic findings in human patients that elevated expression of IL-1β represents a risk 
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factor for gastric cancer, and that IL-1β can synergize with Helicobacter infection to drive cancer 
formation. In addition, it raises the possibility that IL-1β itself may represent a final common pathway 
for Helicobacter pathogenesis. 
Figure 3. H/K-ATPase-IL-1β mouse: Inflammation, Metaplasia and Dysplasia. Low and 
high magnification images of the gastric corpus depicting prominent mucosal and 
submucosal granulocytic and lymphocytic inflammation with oxyntic loss, mucous 
metaplasia, foveolar and glandular hyperplasia, as well as dysplasia characterized by 
glandular architectural abnormalities such as misorientation, splitting, elongation, back to 
back formation, crowding and mild cellular atypia. (Bar: Left 100× or 160 μM, Right 400× 
or 40 μM). 
 
Several molecular mechanisms of cancer development in IL-1β transgenic mice have been 
suggested. First, IL-1β stimulates through the IL-1 receptor the NF-κB pathway, which is strongly 
associated with a variety of cancers. NF-κB activation in inflammatory cells leads to increased 
production of IL-6, TNF-, and other cytokines that have been associated with cancer development. 
Second, IL-1β of tumor cell origin has been shown in other studies to stimulate hematological 
alterations manifested by extensive accumulation in the spleen of Gr-1+CD11b+ immature myeloid 
cells that induce tumor-mediated immune suppression [164]. Indeed, IL-1β transgenic mice showed 
early recruitment of myeloid-derived suppressor cells (MDSCs) to the stomach [163]. Third, a recent 
study suggested that IL-1β suppresses Sonic Hedgehog (Shh) gene expression in parietal cells by 
inhibiting acid secretion and the release of cellular calcium, followed by gastric atrophy [165]. 
The H/K-ATPase-IL-1β mouse model of gastric cancer has been useful for elucidating the 
important contributions of stromal cells in the tumor microenvironments, including CAFs or 
inflammatory cells. Quante et al. showed that at least 20% of CAFs originate from bone marrow (BM) 
and are derived from mesenchymal stem cells (MSCs), and that MSC-derived CAFs which are 
recruited to the dysplastic stomach express IL-6, Wnt5a and BMP4, show DNA hypomethylation, and 
promote tumor growth [31]. Moreover, CAFs are involved in creation of a niche to sustain cancer 
progression in SDF-1-dependent manner [33]. Tu et al. analyzed the role of T cells in gastric 
carcinogenesis by using IL-1β the transgenic model, and reported that IFN-γ overexpression 
suppressed gastric carcinogenesis because helper T cell (Th) 1 and Th17 immune responses were 
inhibited by IFN-γ through Fas induction and apoptosis in CD4 T cells [32]. 
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Taken together, the IL-1β transgenic mouse model is considered to be one of the best mouse models 
of gastric cancer reported to date. In combination with other strains of genetically engineered mice, it 
should be useful for clarifying further the early steps of cancer initiation and the critical interactions 
that take place between the epithelial and stromal components of the gastric mucosa. 
4.5. K-ras Transgenic Mice 
K-ras is one of the most commonly mutated proto-oncogene in a variety of human cancers [166]. 
While normally its activity is tightly regulated, somatic mutations occur that render its activity 
constitutive and thereby oncogenic [167]. Oncogenic activations of K-ras have been found in human 
gastric cancers, although they are not as common (0–18%) in both intestinal type and diffuse type 
gastric cancers as reported in other solid tumors, such as pancreatic or colorectal cancer [168]. While 
oncogenic K-ras leads to increased signaling through a number of proliferative (e.g., MAPK) 
pathways, it has also been strongly linked to the development of chronic inflammation and cancer [169]. 
In genetically engineered mouse models of pancreatic cancer based on PDX1-directed K-ras 
mutations, significant inflammatory and stromal responses correlate with cancer progression [170]. To 
analyze the function of oncogenic K-ras on the stomach cancer development in mice, the K19-promoter, 
which targets expression to the progenitor zone of the gastric neck/isthmus [171], was used to direct 
expression of K-ras-V12 mutant gene. K19-K-ras-V12 transgenic mice (F2 mixed C57BL/6 × DBA 
background) showed an early upregulation of chemokines such as CXCL1 and recruitment of bone 
marrow-derived inflammatory cells and fibroblasts, following by the gradual development of parietal 
cell loss, metaplasia and dysplasia, in a manner that closely resembled H. felis-induced gastric 
preneoplasia and carcinogenesis [171,172]. Thus, these data suggest that K-ras-dependent chronic 
inflammation, leading to the recruitment of bone marrow-derived cells that contribute to the stromal 
microenvironment, can initiate gastric carcinogenesis. 
In a separate study, investigators introduced a conditional K-ras G12D mutation in the K19-positive 
lineage in adult mice by crossing K19-CreERT knock-in mice with LoxP-STOP-LoxP-KrasG12D 
mice. The phenotype of these mice included numerous hyperplasias, metaplasias and adenomas in the 
stomach as well as in the oral cavity, colon and lungs [173]. Another group bred UBC9-CreERT 
transgenic mice with LoxP-STOP-LoxP-KrasG12D mice in order to determine the effect in mice of 
widespread, systemic activation of K-ras [174]. Ubiquitous K-ras activation in mice had rapid and 
dramatic effects on both the forestomach and glandular stomach, and resulted in severe inflammation, 
hyperplasia, metaplasia, and activated progenitor cells, although neoplastic changes in other organs 
were not detected. These latter results suggest that, amongst all the tissues in which K-ras is activated, 
the stomach appears to be unusually susceptible to the effects of K-ras mutation at early time points, 
pointing to a crucial role of K-ras activation in initiation of gastric precancerous changes. 
4.6. Wnt1 and COX-2 Transgenic Mice 
Oncogenic activations of β-catenin have been found in about 20% of intestinal type gastric cancers, 
but not in diffuse type gastric cancers [168,175]. On the other hand, mutation of the Apc gene, while 
extremely common in colorectal cancer, is rarely seen in gastric cancer [168]. Nevertheless, familial 
adenomatous polyposis (FAP) due to germ-line mutations in the Apc gene, and characterized by the 
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formation of thousands of colonic polyps and a high likelihood of colon carcinoma, is also associated 
with an increased risk of gastric polyps and cancer [176,177]. This suggests that Wnt signaling is 
likely to play a causal role in gastric cancer development. Thus, mice carrying a heterozygous Apc 
gene mutation (Apc1648) developed gastric dysplasia and polyposis in the antrum [178]. In addition, 
K19-Wnt1 transgenic mice were noted to have an increase of undifferentiated gastric epithelial cells 
along with the spontaneous development of small preneoplastic lesions in the gastric mucosa [179]. 
These data support a potential role for Wnt signaling in gastric carcinogenesis. 
The COX-2/PGE2 pathway is also thought to play an important role in gastric tumorigenesis. 
Overexpression of cyclooxygenase 2 (COX-2) is frequently detected in gastric cancer [180]. COX-2 
transgenic mice, where the human COX-2 cDNA was driven from the cytomegalovirus (CMV) 
promoter, showed an increase in MNU-induced gastric cancer development [55]. Treatment with 
celecoxib, a selective COX-2 inhibitor, reduced MNNG-induced gastric cancer incidence and growth 
in rats [181]. A combination of sulindac (a nonspecific COX inhibitor) and antimicrobial eradication 
prevent progression of gastric cancer in H. pylori-infected INS-GAS mice [182]. Finally, hyperplastic 
gastritis induced by H. pylori is associated with upregulated COX-2 expression, and gastric 
hyperplasia was significantly reduced by treatment with the selective COX-2 inhibitors [183–185]. 
In 2004, K19-C2mE transgenic mice were reported that simultaneously expressed both COX-2 and 
microsomal prostaglandin E synthase (PGES)-1 in the gastric epithelial cells. The transgenic mice 
developed hyperplastic lesions, metaplasia (SPEM), and tumorous growths in the glandular stomach 
with heavy macrophage infiltrations [186,187]. These findings suggest that an increased level of PGE2 
enhances macrophage infiltration, thus contributing to gastric tumor development. When K19-Wnt1 
mice were crossed with K19-C2mE to construct compound transgenic mice (K19-Wnt1/C2mE mice), 
the K19-Wnt1/C2mE mice developed mucous metaplasia followed by the spontaneous development of 
gastric adenocarcinoma [179]. The tumors consisted of dysplastic epithelial cells, which sometimes 
invaded the smooth muscle layers. These results clearly indicate that the simultaneous activation of the 
Wnt and PGE2 pathways can promote dysplastic gastric tumors through a metaplasia-carcinoma 
sequence. Moreover, ablation of CD44 (a gastric cancer stem cell marker [188]) in K19-Wnt1/C2mE 
mice (i.e., CD44
−/−
K19-Wnt1/C2mE mice) suppressed gastric tumor growth [189], suggesting that 
CD44-targeted therapy may impair tumor growth ability. 
4.7. Other Mouse Models of Gastric Cancer 
Other murine models have been reported that show a significant gastric neoplastic phenotype, and 
these will be discussed briefly. These have included manipulations of genes in the TGF-β/Smad 
pathway, RUNX3, MLH1/MSH2, p53, KLF4 and CDH1 (Table 2). 
The TGF-β/Smad signaling pathway is commonly altered in gastric cancer [190–192], and TGF-β1 
knockout mice (mixed C57BL/6/Sv/129 background) developed severe epithelial hyperplasia and 
metaplasia in the stomach [193]. Hahm et al. established TGF-β2 dominant-negative mice (mixed 
C57BL/6 × Sv/129 background) under the TFF1 promoter, and these mice showed a higher proliferation 
index and a higher incidence of gastric cancer with H. pylori infection [194]. Heterozygous Smad4 
knockout mice (mixed C57BL/6 × Sv/129 background and C57BL/6 background) exhibited 
spontaneous gastric tumor development [195,196]. Interestingly, T-cell specific deletion of Smad4 
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induces gastric tumors, as well as colon, duodenal and oral cavity tumors, with induction of inflammatory 
cytokines [197,198]. 
Table 2. Mouse models of gastric cancer. 
Model Incidence Duration Location Phenotype 
MNU <70% 12 months Antrum AdenoCa, Dysplasia [11,47–49] 
H. felis 80% 18 months SCJ/Transition 
AdenoCa, Dysplasia, Metaplasia, Atrophy 
[21] 
MNU + H. pylori 80% 12 months Antrum 
AdenoCa, Dysplasia, Metaplasia, Atrophy 
[110] 
MNU + H. felis 100% 36 weeks Antrum 
AdenoCa, Dysplasia, Metaplasia, Atrophy 
[60] 
CEA/SV40 100% 50 days Antrum 
AdenoCa, Dysplasia, Invasion to 
submucosa and duodenum [24] 
MMTV/Ad12 82%(male) 3–4 months SCJ AdenoCa, AdenosquamousCa [26] 
HPV-16 100% 246–352 days Antrum 
Carcinoid, Metastasis to lymph node and 
liver [27] 
MTH1−/− 13% 18 months Antrum 
AdenoCa, Dysplasia, Hyperplasia, Lung 
and liver tumors [199] 
TFF1−/− 30% 5 months Antrum 
Intramucosal carcinoma, Hyperplasia, 
Activation of NF-kB [144,145] 
Smad4
+/−
 100% 12–18 months Corpus/Antrum 
AdenoCa, Dysplasia, Hyperplasia, 
Duodenal tumor [195,196] 
GB-Smad4F/F 100% 12–18 months Antrum Dysplasia, Hyperplasia [197] 
INS-GAS 75% 20 months Corpus 
AdenoCa, Dysplasia, Metaplasia, Atrophy, 
Synergized with H. felis [29] 
GAS−/− 60% 12 months Antrum 
Dysplasia, Metaplasia, Atrophy, 
Susceptible to MNU [60,143] 
Gp130F/F 100% 6 months Antrum 
Adenoma, Decreased TFF1 expression 
[158,159] 
IL-1β <70% 12 months Transition 
AdenoCa, Dysplasia, Metaplasia, Atrophy, 
Synergized with H. felis [163] 
K19/K-ras 37.5% 16 months Corpus Dysplasia, Metaplasia, Atrophy [172] 
Wnt1/C2me 100% 20 weeks SCJ 
AdenoCa, Dysplasia, Metaplasia, 
Attenuated by CD44 ablation [179,189] 
CDH1+/− + MNU 45.8% 40 weeks Antrum Signet-ring cell Ca, Adenoma [56] 
CDH1/p53 100% 12 months Corpus 
Poorly differentiated AdenoCa, Signet-
ring cell Ca [200] 
RUNX3−/− + 
MNU 
71% 52 weeks Corpus/Antrum AdenoCa, Metaplasia, Hyperplasia [201] 
Villin-KLF4F/F 29% 80 weeks Antrum Adenoma, Susceptible to MNU [57] 
RUNX3 is a member of the RUNX gene family which regulates the Smad gene family transcription 
and TGF-β signaling. RUNX3 is frequently inactivated in gastric cancer by protein mislocalization [202]. 
RUNX3 knockout mice (F2 offspring) showed elongated gastric glands and increased proliferation in 
the gastric mucosa [203]. Ito et al. recently reported that RUNX3 knockout mice (Balb/c background) 
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showed loss of chief cells and development of SPEM, and also displayed higher susceptibility to 
adenocarcinoma by treatment with MNU [201], supporting a role for RUNX3 as a tumor suppressor of 
gastric cancer. 
Interestingly, alterations in p53 and DNA mismatch repair genes in mice have not produced 
dramatic gastric phenotypes, pointing to important differences between mice and humans. Alterations 
in DNA mismatch repair genes, such as MLH1 and MSH2, are associated with the Lynch syndrome 
(formerly known as hereditary non-polyposis colorectal cancer or HNPCC), which is characterized 
with increases in not only colorectal cancer but also ovarian, endometrium, liver, skin, brain, and 
gastric cancer [204]. However, mice lacking MLH1 or MSH2 do not develop gastric cancer, even with 
H. felis infection (Fox JG and Wang TC, unpublished data). Similarly, the p53 gene is the most commonly 
mutated tumor suppressor in a wide variety of human cancers. However, while H. felis-infected p53 
hemizygous mice were reported to have a higher proliferative index and a higher gene mutation 
frequency than the infected control mice [205,206], they did not show increased progress to gastric 
cancer, although p53 heterozygous mice were more sensitive than WT counterparts to MNU [50,207]. 
However, a subsequent study demonstrated that the incidence of pre-neoplastic and invasive gastric 
carcinomas was decreased in p53 hemizygous mice [21], and an independent group reported that no 




 mice after infection 
with H. pylori SS1 strain [208]. These results point to the limitations of using constitutive p53 
knockout mice in modeling gastric cancer in mice, given the likely distinct roles of p53 in epithelial 
cells and inflammatory cells. 
Krüppel-like factor 4 (KLF4) is a potential tumor suppressor in patients with various cancers, 
including gastric cancer [209]. Disruption of Klf4 in mice using the Villin-Cre-mediated system, which 
targets not only the intestine but also antral stem/progenitor cells [57] induced spontaneous antral 
tumors. MNU treatment enhanced cancer development in these mice. Therefore, inactivation of Klf4 in 
Villin-positive gastric progenitor cells can lead to transformation of the gastric mucosa and 
tumorigenesis of the gastric antrum. 
To date, most murine models that develop gastric cancer have shown similarities to the well 
differentiated, intestinal-type of gastric cancer, but not to the diffuse type of gastric cancer. In human 
gastric cancer, loss of expression of the CDH1 gene encoding for E-cadherin has frequently been 
detected [210], often due to promoter hypermethylation [168,211], particularly in diffuse-type lesions. 
Germline mutations of the CDH1 gene have been observed in hereditary diffuse type gastric cancer [212]. 
CDH1 knockout mice (C57BL/6 background) have been generated, and in the MNU carcinogenesis 
model, CDH1
+/−
 mice developed signet ring cell carcinoma with a high tumor incidence rate [56]. 
Recently Shimada et al. generated conditional CDH1 and p53 double knockout mice under targeting 
by the H/K-ATPase promoter [200]. In these conditional double knockout mice, intramucosal and 
invasive cancers composed of signet ring cells were found from 6 to 9 months, while mice lacking 
only the CDH1 gene developed no cancers. These observations support the notion that CDH1 plays a 
critical role in especially diffuse type gastric cancer, but mouse gastric cancer development requires 
not only CDH1 loss but also an additional mutation or carcinogen exposure. 
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5. Models of Precancerous Change 
H. pylori-associated gastric cancer in humans is preceded by a cascade of precancerous lesions, and 
cancer emerges following a number of discrete stages, including chronic gastritis, gastric atrophy, 
intestinal metaplasia, and dysplasia. Thus, in addition to mouse models of gastric cancer, there are a 
number of genetically engineered models that show decreased numbers of parietal cells, or gastric 
atrophy, along with metaplasia. In this section, we review briefly a number of models of atrophy and 
metaplasia that could be considered for use in experimental studies (Table 3). However, most of these 
models do not appear to progress to neoplasia, and most have not been examined for susceptibility to 
cancer in response to carcinogens. 
Table 3. Mouse models of precancerous changes. 
Model Duration Phenotype 
H.pylori (SS-1) 6–9 months Atrophy, SPEM [20] 
TGF- transgenic 3 months Atrophy [122,213] 
H/K-ATPase/DT 28–80 days Atrophy [214] 
H/K-ATPase/Tk Ganciclovir treatment Atrophy [215] 
H/K-ATPase-−/− 10 weeks Atrophy [216] 
H/K-ATPase-β−/− 17 days Atrophy [217,218] 
NHE2−/− 17 days Atrophy [219] 
Car9−/− 4 weeks Atrophy [220] 
CCK2R−/− 18 weeks Atrophy [221,222] 
H/K-ATPase/Shh−/− 3–8 months 
Pit cell hyperplasia, loss of parietal cell 
function [223] 
DMP-777 7–14 days Atrophy, SPEM [224,225] 
L-635 7 days Atrophy, SPEM [226] 
Cdx2 transgenic 120 days Intestinal metaplasia [227,228] 
Cdx1 transgenic 120 days Intestinal metaplasia [229] 
5.1. Models of Gastric Atrophy 
There are a number of genetically engineered mouse models, which exhibit parietal cell loss, i.e., 
gastric atrophy. Indeed, one strategy to achieve more rapid progression to gastric cancer is to ablate 
parietal cells, which appear to protect the homeostasis of the stomach in part through acid secretion. As 
mentioned above, MT-TGF-α transgenic mice show a form of atrophic gastritis, with loss of parietal 
cells along with foveolar hyperplasia [122,213]. Using the promoter of the β-subunit of the H/K-ATPase 
gene driving diphtheria toxin or herpes simplex 1 thymidine kinase, researchers were able to partially 
ablate parietal cells [214,215]. Interestingly, with loss of mature parietal cells in both of these models, 
there was concomitant loss of chief or zymogenic cells, along with an increase in progenitor cells. 
Thus, accumulating data indicate that the parietal cell itself or its secreted products plays a critical role 
on maintaining gastric gland homeostasis and controlling the development of cancerous changes.  
In many of these mouse models with impaired parietal cell function, hypochlorhydria leads to 
hypergastrinemia, which then induces foveolar hyperplasia. Thus, mice with a disrupted H/K-ATPase 
β-subunit gene exhibit abnormal parietal cell morphology, achlorhydria, hypergastrinemia, and 
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hypertrophied gastric mucosa [216,217]. When crossed with GAS
−/−
 mice, gastric hypertrophy in the 
H/K-ATPase-β-deficient mice disappeared, confirming that this phenotype is largely hypergastrinemia-
dependent [218]. Similarly, targeted disruption of the Na+/H+ exchanger isoform 2 (NHE2) gene or 
carbonic anhydrase gene have also been reported to induce parietal cell loss [219,220]. Transgenic 
mice with parietal cell-specific deletion of Sonic Hedgehog (Shh) (H/K-ATPase-Cre/Shh
−/−
) also 
developed gastric hypochlorhydria, hypergastrinemia, and a phenotype that resembled foveolar 
hyperplasia with hyperproliferation of surface mucous cells [223]. Therefore, Shh may also function as 
a gastric morphogen, regulating gastric epithelial cell function and differentiation. In contrast, mice 
deficient in gastrin or its receptor cholecystokinin-B exhibit impaired acid secretion and reduced 
parietal cell numbers, but do not show foveolar hyperplasia [141,221,222,230]. As noted above, gastrin 
knockout mice are more susceptible to mouse induced antral carcinogenesis, but most other mouse 
models have not been tested in carcinogenesis trials. 
5.2. Models of Metaplasia 
Recently, it has become clear that there are two distinct types of metaplasia in the stomach that 
precede and are associated with gastric cancer [231]. (1) Spasmolytic polypeptide-expressing 
metaplasia (SPEM), also known as pseudopyloric metaplasia, is characterized by the presence of 
TFF2- and MUC6-immunoreactive cells in the gastric fundus with morphological characteristics 
similar to deep antral gland cells or Brunner’s gland cells. (2) The other is classical intestinal 
metaplasia (IM), which is characterized by the presence of cells with the morphology of goblet cells 
and expression of MUC2 and TFF3. Both types of metaplasia are Alcian blue-positive. For many 
years, IM was thought to be a direct precursor of gastric cancer; however, while the association of 
intestinal-type cancers with chronic H. pylori infection and oxyntic atrophy in human is well accepted, 
little evidence directly links intestinal metaplasia with dysplastic transformation [232]. Indeed, many 
investigators have come to the conclusion that SPEM is more likely to be the relevant precursor to 
gastric adenocarcinoma [233]. 
In most of the mouse models progressing to dysplasia described above, including mouse models of  
H. felis infection and transgenic mouse models (such as INS-GAS and H/K-ATPase-IL-1β mice), 
which demonstrate severe parietal cell loss, the fundic mucosa is replaced with a mucous cell 
metaplasia which was shown to be TFF2-expressing SPEM. Importantly, in these mouse models which 
progress to cancer, SPEM represents the only observed metaplasia, with no goblet cell IM being 
present. In addition, a short term model of parietal cell ablation has been described, using the 
neutrophil elastase inhibitor, DMP-777, which was shown to be a parietal cell-specific protonophore. 
DMP-777 treatment has allowed the examination of SPEM induction after acute oxyntic atrophy in the 
absence of significant inflammatory infiltrate. Mice or rats treated for 3 days with DMP-777 
demonstrate a rapid loss of parietal cells [224,225]. The acute oxyntic atrophy is followed by SPEM in 
the fundus after 7–10 days. A structurally related β-lactam compound L-635, which retains potent 
parietal cell protonophore activity, but does not have any significant activity against neutrophil 
elastase, also induces gastric atrophy. In contrast with DMP-777 treatment, submucosal and 
intramucosal inflammatory infiltration was observed, and L-635 caused a more rapid and marked 
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mucous cell TFF2-positive metaplasia [226]. These results indicated that a combination of parietal cell 
loss and inflammation could potentiate the development of SPEM. 
Transgenic mice expressing the intestine-specific homeobox gene, Cdx2, under H/K-ATPase or 
Foxa3 promoter showed the disappearance of parietal cells and the replacement by classical IM [227,228]. 
Moreover, mice overexpressing Cdx1, another intestine-specific homeobox gene, also developed IM [229]. 
However, no further progression to gastric carcinogenesis was observed in these transgenic mice, 
consistent with the notion that IM may not be the primary precursor of gastric cancer. However, the 
effect of Helicobacter infection on the gastric phenotype of these mice has not been assessed. Thus, 
further studies are needed to clarify the precise relationship between classical intestinal metaplasia and 
malignant transformation. 
6. Conclusions and Future Perspectives 
Numerous mouse models with interesting gastric phenotypes are now available for studies of gastric 







), Helicobacter infection (H. felis, H. pylori) and carcinogen 
(MNU) models. These models have defined potential roles for gender, diet, bacterial flora, inflammatory 
cytokines, T helper immune response, acid secretion, virulence, and colonization properties of H. pylori 
strains and host genetic background. Reasonable models are now available for studies of early stage 
pathogenesis and cancer prevention. 
The mouse stomach consists of four different parts: forestomach, cardia, corpus, and antrum. Some 
models have been described in which forestomach tumor, i.e., squamous cell carcinoma, is induced 
with a carcinogen or by genetic alterations [26,46,47]. These models are not useful for investigating 
the mechanism of human gastric cancer, as humans do not have a forestomach and gastric squamous 
cell carcinoma is very rare. While there has been no model that resembles human cardia cancer, a 
variety of corpus and antral cancer models have been reported as described above. However, in order 
to select appropriate mouse models of gastric cancer, investigators need to consider the histopathology, 
the cell type of origin and the geographic distribution of the resultant cancer. Sometimes, a given 
physiological stimuli will show a different phenotype between the corpus and antrum, such as seen in 
gastrin transgenic and knockout mice [29,60,143]. 
Unfortunately, genetic models of metastatic gastric cancer similar to those developed for pancreatic 
cancer, comprising two or three mutations targeted to specific cell lineages, are not available. These 
models could facilitate preclinical studies and the testing of newer therapeutics. The major limitations 
in the development of these models have been the weak and scattered activity of promoters used in the 
stomach and the lack of stomach specific promoters that target antral progenitors but are not expressed 
elsewhere (Table 4). K19-Cre and Foxa3-Cre constructs, for example, are expressed in the stomach 
and can be used as a model for the analysis of gastric cancer, but these promoter constructs are also 
expressed in the intestine, colon and pancreas, as well as other tissues [105,172]. Recent lineage 
tracing studies revealed several stem/progenitor markers of gastrointestinal tissue, including Lgr5, 
Bmi1, Hopx, Lrig, Sox2, and Sox9 [234–239]. Among them, Lgr5, Lrig, and Sox2 have been reported 
to be expressed in the mouse stomach. Lgr5 positive cells are likely to be stem cells in the gastric  
antrum [234,240], and can be used for mutagenic targeting to the distal stomach, but Lgr5 is also 
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widely expressed in the intestine and elsewhere making targeted stomach mutations impractical. 
Similarly, Lrig and Sox2 are expressed in the intestine and other organs as well as the stomach. Villin-Cre 
constructs also can target antral glands, but are also expressed in whole intestine [241]. On the other 
hand, stomach specific promoters such as the H/K-ATPase promoter are not ideal since they target 
more mature parietal cells, which are unlikely to be the precursor lineage of distal gastric cancers. 
Table 4. Promoters for establishing gene expression in the stomach. 
Gene Location Lineage tracing in the stomach 
TFF1 Surface of stomach (pit cell area)  
TFF2 Isthmus of corpus & base of antrum Give rise to parietal, mucous neck, and chief cells [242] 
H/K-
ATPase 
Corpus (parietal cell) 
Give rise to all gastric lineages of the corpus glands 
with Notch activation [243] 
Foxa3 Whole stomach, other organ from endoderm  
K19 Whole stomach, intestine, colon, etc.  
Lgr5 Cardia, Antrum, intestine, colon, etc. 
Give rise to all major cell types in the cardia, antrum 
and transition zone [240] 
Sox2 
Corpus, Antrum, Esophagus, Forestomach, 
etc. 
Give rise to all major cell types in the corpus and the 
antrum [236] 
Mist1 Corpus (chief cell), Brunner gland, pancreas Give rise to chief cell and drug-induced SPEM [226] 
Villin Antrum, intestine, colon 
Give rise to all gastric lineages of the antral glands 
with IFN-γ treatment [241] 
One potential candidate for a gastric targeting vector might be TFF1, which shows specific 
expression in foveolar cells of the stomach. To date, one study has reported the use of the TFF1 
promoter to disrupt TGF-β2 specifically in the stomach [194]. Further studies using TFF1-specific 
gene engineering should be considered. Both TFF2-CreERT and Mist1-Cre mice are available. In the 
corpus, TFF2 and Mist1 are known to be potent progenitor cell lineages. Mist1-expressing cells in the 
stomach give rise to SPEM after stimulation [226]. TFF2mRNA-expressing cells are localized to the 
isthmus and are progenitors for mucus neck, parietal and zymogenic cells, but not for pit or 
enterochromaffin-like cell lineages [242]. TFF2 is also expressed in the base of the antral glands, 
suggesting that TFF2 could be a potent candidate promoter vector for targeting the stomach. In order to 
obtain stomach-specific gene control, other stomach-specific stem/progenitor markers should be 
explored by using emerging lineage tracing technique in vivo and stem cell culture methods in vitro. 
Recent exome sequencing or GWAS studies have clarified significant gene mutations in human 
gastric cancer, such as PSCA, PLCE1, FAT4 and ARID1A [244–247]. Newer mouse models which 
contain these gene alterations should be useful for investigating the function of these genes. In turn, 
comprehensive analysis of genetic and epigenetic changes of mouse gastric cancer should also be 
helpful for identifying additional genetic changes or epigenetic modifications which are not covered by 
exome sequencing or GWAS studies focusing on human gastric cancer. 
In summary, several mouse models of gastric cancer are available, which have distinct mechanisms, 
as well as different tumor phenotypes such as time course, locations, and pathology. Researchers are 
thus able to use appropriate mouse models for their studies and are commensurate with their rationale 
and hypothesis. Newly emerging research methods, including lineage tracing or genome-wide 
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comprehensive analysis, and also by examining non-epithelial targets, should prove helpful for 
understanding both the cause and ultimately the cure of gastric cancer. 
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